| 摘要 |
<p>RANTES mutants, characterized by the substitution or addition of amino acids at the N-terminal, in the N-loop and/or 40's loop regions of RANTES wild-type sequence, are new. A RANTES mutant (I) is characterized by at least one amino acid mutation at the N-terminal, in the N-loop and/or 40's loop regions of RANTES wild-type sequence, the mutant having the capability to competitively antagonize wild-type RANTES, MIP-Ialpha or MIP-Ibeta , or to antagonize the interaction between HIV virus and a chemokine receptor. Independent claims are also included for the following: (1) a peptide derived from RANTES sequence of N-terminal, N-loop or 40's loop regions comprising a mutation as in (I); (2) a wild-type RANTES with an additional amino acid at the N-terminus, where the amino acid is Cys; (3) a nucleotide sequence encoding a RANTES mutant as in (I); (4) a vector for eukaryotic or prokaryotic expression comprising the nucleotide of (3); and (5) a process for preparing RANTES mutants as above, which comprises culturing eukaryotic cells transfected with vectors containing DNA fragments encoding the mutants. ACTIVITY : Anti-HIV; Anti-allergic; Anti-Asthmatic; Anti-Inflammatory. MECHANISM OF ACTION : Chemokine Antagonist.</p> |
